Memantine Hydrochloride Tablets.

Memantine hydrochloride is used to treat moderate to severe to severe Alzheimer’s dementia.
It is contraindicated for people who are allergic to the active ingredients and excipients of this product, pregnant women, and breastfeeding women. … Details 
Comprehensive interpretation of memantine hydrochloride

Effects and efficacy:
It is used to treat moderate to severe to severe Alzheimer’s dementia.
Usage and dosage:
The maximum daily dose for adults is 20 mg. In order to reduce the occurrence of adverse reactions, the maintenance dose should be gradually reached by increasing the dose by 5 mg per week in the first 3 weeks of treatment, as follows: the dose in the first week of treatment is 5 mg per day (half a tablet each time), 10 mg per day in the second week (one tablet each time, once a day), 15 mg per day in the third week (one and a half tablets each time), and the recommended maintenance dose is 20 mg per day (two tablets each time, once a day) starting from the fourth week. Elderly patients According to the results of clinical studies, the recommended dose for patients over 65 years old is 20 mg per day (two tablets each time, once a day). Children and adolescents Since there is no safety and efficacy data for this product in children and adolescents, this product is not recommended for children and adolescents. Patients with renal insufficiency For patients with mild renal insufficiency (creatinine clearance 50-80ml/min), no dose adjustment is required. For patients with moderate renal insufficiency (creatinine clearance 30-49ml/min), the dose of memantine should be reduced to 10mg per day; if the patient can tolerate it well after at least 7 days of treatment, the dose can be increased to 20mg/day according to the standard dose adjustment scheme. For patients with severe renal insufficiency (creatinine clearance 5-29ml/min), the dose of memantine should be 10mg per day. Patients with hepatic insufficiency Patients with mild to moderate hepatic insufficiency (liver function graded as Child-Pugh A and Child-Pugh B) do not need to adjust the dose. There is currently no data on the use of memantine in patients with severe hepatic insufficiency. This product is not recommended for patients with severe hepatic insufficiency. The same drugs produced by different manufacturers may have inconsistent instructions. If you find that the contents of the drug instructions are inconsistent before taking the drug, please consult a doctor or pharmacist in time.
Contraindications:
Contraindicated if allergic to this product; contraindicated during pregnancy; contraindicated during lactation
Related dosage forms:
Tablets, oral solution